Vivitrol vs Naltrexone, Acamprosate, and Disulfiram for Alcohol Use Disorder
Four FDA-approved medications treat alcohol use disorder. Vivitrol, oral naltrexone, acamprosate, and disulfiram. They work through completely different mechanisms and they fit different patients. Picking based on what your prescriber happens to be familiar with rather than which medication actually fits your situation is one of the most common avoidable mistakes in AUD treatment.
| Attribute | Vivitrol | Oral naltrexone | Acamprosate (Campral) | Disulfiram (Antabuse) |
|---|---|---|---|---|
| Mechanism | Opioid receptor blocker | Opioid receptor blocker | GABA/glutamate modulator | Aldehyde dehydrogenase inhibitor |
| FDA approval year | 2006 for AUD | 1994 for AUD | 2004 | 1951 |
| Form | Monthly IM injection | Daily 50mg tablet | Three 333mg tablets, 3x daily | Daily 250mg to 500mg tablet |
| Effect on drinking | Reduces heavy drinking days, weakens reward | Same as Vivitrol | Reduces post-acute withdrawal cravings | Aversive reaction if alcohol consumed |
| Best for | Reducing heavy drinking | Reducing heavy drinking | Maintaining abstinence after detox | Patients with strong external motivation |
| Pre-treatment requirement | 7 to 10 days opioid-free | 7 to 10 days opioid-free | Abstinent at start | Abstinent at start |
| Liver issues | Hepatotoxicity warning | Hepatotoxicity warning | Generally well tolerated | Severe hepatic effects possible |
| Adherence | 28-day guaranteed | Poor without structure | 9 pills per day - difficult | Often supervised by family |
| Cost without insurance | ~$1,500 per shot | ~$30 to $80 per month | ~$80 to $200 per month | ~$30 to $100 per month |
| Pregnancy category | Avoid | Avoid | Generally considered safer | Avoid |
| Renal monitoring | Not required | Not required | Required - dose adjusted for renal function | Not required |
The mechanism map, in plain language
Naltrexone (oral or Vivitrol) blocks the opioid receptors that alcohol indirectly activates. Drinking on naltrexone produces less of the pleasure signal that drives the next drink. It does not stop you from drinking. It weakens the loop. Patients on naltrexone often describe drinking and feeling nothing, or drinking three beers and not wanting a fourth.
Acamprosate works on a different system entirely. It modulates GABA and glutamate, the two neurotransmitters that go haywire during alcohol withdrawal and post-acute withdrawal. It does not affect the reward circuit. It targets the discomfort that drives early-recovery patients to drink. Patients on acamprosate describe feeling more stable, less anxious, less restless.
Disulfiram works through aversion. It blocks the enzyme that breaks down acetaldehyde, the toxic metabolite of alcohol. Drink on disulfiram and you get a flushing, headache, vomiting, racing heart reaction within 30 minutes. The medication does not reduce cravings. It just makes drinking physically punishing. It works as long as the patient takes it.
Who Vivitrol fits best for AUD
- Patients with frequent heavy drinking days who want to reduce them
- Patients who have failed daily medication adherence
- Patients with co-occurring opioid use disorder
- Patients in early recovery who want a single monthly anchor instead of daily decisions
Who acamprosate fits best
- Patients who have already detoxed and want to stay abstinent
- Patients who report ongoing anxiety, sleep disturbance, or restlessness in early recovery
- Patients who cannot take naltrexone because they need opioid pain medication
- Patients without significant kidney impairment
Who disulfiram fits best
- Patients with strong external motivation (probation, professional licensing, family contract)
- Patients with a partner or family member who can supervise daily dosing
- Patients who have failed other medications and need an aversive backup
- Patients who are highly motivated and want a tool that removes the drinking option entirely
What the trial evidence says
The COMBINE study (the largest US AUD pharmacotherapy trial, published in JAMA 2006) compared naltrexone, acamprosate, both, and behavioral intervention in 1,383 patients. Naltrexone reduced heavy drinking days. Acamprosate did not show significant effect on top of behavioral intervention in that trial, though European trials with longer durations showed clearer benefit. Disulfiram has weaker controlled trial evidence overall but stronger evidence in supervised dosing arrangements.
Vivitrol's pivotal trial (Garbutt et al., 2005, JAMA) showed a 25% reduction in heavy drinking days versus placebo over six months. The advantage over oral naltrexone in real-world adherence settings tends to be larger than in trial settings, because oral adherence is artificially elevated in trial conditions.
Combinations
Vivitrol plus acamprosate is sometimes prescribed for patients with both reward-driven and discomfort-driven drinking. The combination has not been studied in large trials but the mechanisms do not conflict. Vivitrol plus disulfiram is rarely used. Naltrexone plus disulfiram has been studied with mixed results.
The honest take
Most AUD patients in the United States are not offered any medication. The default is "AA and counseling." That is a failure of the medical system. Of the four FDA-approved medications, Vivitrol has the strongest combination of efficacy, adherence, and patient acceptability. It is also the most expensive at sticker. For patients with insurance, especially Medicaid, the cost barrier is small enough that Vivitrol should be the first conversation rather than the last.